NCT04493281View on ClinicalTrials.gov

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 22, 2019

Primary Completion Date

April 21, 2019

Study Completion Date

May 9, 2019

Conditions
Healthy Adult Subjects
Interventions
DRUG

MT-1186

Oral suspension

DRUG

MCI-186

Intravenous formulation

Trial Locations (1)

Unknown

Investigational site, Tokyo

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY